Kadcyla 160 MG vials
Ended Awarded
- Contract number
- SPE2DR26FCRG4
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $17,320
Award facts
- Contract value 100% obligated
- $17,320.32 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a delivery order valued at $17,320.32 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler headquartered in Park Ridge, Illinois, for the supply of Kadcyla 160 mg vials. The award, issued on November 4, 2025, with an ultimate completion date of November 26, 2025, utilizes a firm fixed-price contract structure without a set-aside designation, demonstrating the contractor's competitive capability in unrestricted federal procurement. DMS Pharmaceutical Group Inc. will perform the delivery order at its Park Ridge facility and has been registered in the System for Award Management since July 2001.
This delivery order is issued under DMS Pharmaceutical Group's single-award Indefinite Delivery Contract (IDC) designated SPE2DR within the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative. The underlying IDC, awarded November 13, 2025, carries a $500 million ceiling value and extends through December 31, 2036, with a 30-month base period followed by three optional 30-month periods. The PPV-G GEN V represents part of the broader $30.3 billion acquisition strategy designed to ensure consistent pharmaceutical supply to military healthcare facilities worldwide. DMS Pharmaceutical Group's established performance across numerous delivery orders demonstrates its capability to fulfill the specialized pharmaceutical requirements of the Department of Defense healthcare system, including oncology treatments, biologics, vaccines, and emergency medications.
Quick answers
Who was awarded contract SPE2DR26FCRG4?
SPE2DR26FCRG4 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on November 4, 2025.
How much is contract SPE2DR26FCRG4 worth?
The government has obligated $17,320 on SPE2DR26FCRG4.
Is contract SPE2DR26FCRG4 an order under another contract?
Yes. SPE2DR26FCRG4 is a delivery order under SPE2DR25D9168, an indefinite delivery contract.
Was contract SPE2DR26FCRG4 competed?
The extent of competition for SPE2DR26FCRG4 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award